On November 30, the "2023 Forbes China ESG Innovative Enterprise Selection" dinner and awards ceremony was held in Shenzhen. For its outstanding performance in the field of ESG innovation practices, Sino Biopharm was successfully named a "2023 Forbes China ESG Innovative Enterprise".

The "2023 Forbes China ESG Innovative Enterprise" list, launched by Forbes China, aims to showcase the differentiated advantages of pioneering enterprises in the field of ESG innovation and their outstanding contributions to regional and even global challenges, helping the entire business community move toward a more sustainable future.

This selection revolves around four major dimensions: "Corporate Growth", "ESG Practice", "Innovation Execution", and "Industry Influence". It covers multiple industries, including pharmaceuticals, finance, energy, environmental protection, industrial manufacturing, real estate, and enterprise technology, to recognize representative samples of ESG innovation in Chinese enterprises, showcase their ESG innovation achievements, and analyze and discover the current status and future trends of ESG development in China. After several months of evaluation by expert judges, Sino Biopharm ultimately stood out for its highly forward-looking and innovative practices in the ESG field.

As a leading innovation and R&D-driven pharmaceutical group in China, Sino Biopharm has always adhered to technological innovation, continuously accelerating differentiated and international innovation, and contributing more of China's strength to promoting the high-quality development of the Chinese pharmaceutical industry and building a global community of health for all. In 2022, the Group's R&D investment reached RMB 4.454 billion, with a year-on-year increase of 16.6%. In terms of absolute value, growth rate, and investment proportion, Sino Biopharm's investment in innovative R&D is at the forefront of the industry. Currently, the company's innovation transformation has entered a harvest period. In 2022, the net income from innovative drugs reached RMB 6.75 billion, with a year-on-year increase of 20%.

While adhering to innovative R&D, Sino Biopharm upholds the concept of sustainability and is committed to earnestly practicing the Group's corporate mission of "improving the quality and protecting the dignity of human life" through high-quality ESG management. It has carried out numerous ESG innovation practices in corporate governance, environmental protection, and social responsibility, and achieved excellent results.

In terms of corporate governance, the Group continuously enhances the professionalism, independence, and diversity of its Board of Directors, ensuring full consideration of ESG in all major decision-making processes. At the same time, the Group is committed to conducting its business activities in accordance with the highest ethical standards, building a transparent, honest, and moral business ecosystem, and striving to create a corporate culture of integrity and transparency.

In terms of environmental protection, Sino Biopharm has always practiced the concept of green development and continuously builds environmentally friendly enterprises. Several of its key member companies have been awarded provincial and national "Green Factory" titles. At the same time, the Group has officially launched the "Carbon Neutrality Pathway Planning Project", systematically promoting low-carbon transformation measures such as process optimization, upgrading of high-energy-consumption equipment, application of renewable energy, and construction of a green industrial chain to effectively reduce greenhouse gas emissions.

In terms of social responsibility, Sino Biopharm actively innovates and develops various public welfare and charitable activities, contributing to philanthropic causes. Since 2020, the Group's member company Chia Tai Tianqing has jointly launched the "Clear Sky Program" public welfare project with multiple parties to raise funds for families of patients with serious illnesses who are in need, helping them overcome their difficulties. As of October 2023, the project has raised a total of over RMB 26 million, with more than 1.47 million participations in fundraising.

In the future, Sino Biopharm will continue to drive corporate development through innovation, work with employees and partners from all sectors to create a sustainable future, integrate knowledge with action through careful consideration, seek health and well-being for more patients, create win-win situations for the environment and society, and help society move toward a more sustainable future.